VIRACTA THERAPEUTICS INC (VIRX) Stock Price, Quote, News and Overview
NASDAQ:VIRX - Nasdaq - US92765F1084 - Common Stock - Currency: USD
VIRX Quote, Performance and Key Statistics
0.0778
-0.07 (-48.65%)
The current stock price of VIRX is 0.0778 USD. In the past month the price decreased by -56.02%. In the past year, price decreased by -87.45%.
VIRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.9 | 373.82B | ||
| AMGN | AMGEN INC | 15.97 | 170.00B | ||
| GILD | GILEAD SCIENCES INC | 25.04 | 143.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1695.31 | 126.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.12B | ||
| ARGX | ARGENX SE - ADR | 247.66 | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.98B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.51B | ||
| BIIB | BIOGEN INC | 8.73 | 20.95B | ||
| NTRA | NATERA INC | N/A | 19.53B | ||
| GMAB | GENMAB A/S -SP ADR | 25.37 | 15.31B |
Related stock screener links
About VIRX
Company Profile
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Company Info
VIRACTA THERAPEUTICS INC
2533 S Coast Hwy 101, Suite 210
Cardiff-by-the-Sea CALIFORNIA 94080 US
CEO: Parvinder Hyare
Employees: 40
Company Website: https://www.viracta.com/
Investor Relations: https://viracta.investorroom.com/governance-documents
Phone: 18584008470
VIRACTA THERAPEUTICS INC / VIRX FAQ
What is the stock price of VIRACTA THERAPEUTICS INC today?
The current stock price of VIRX is 0.0778 USD. The price decreased by -48.65% in the last trading session.
What is the ticker symbol for VIRACTA THERAPEUTICS INC stock?
The exchange symbol of VIRACTA THERAPEUTICS INC is VIRX and it is listed on the Nasdaq exchange.
On which exchange is VIRX stock listed?
VIRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VIRACTA THERAPEUTICS INC stock?
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778. Check the VIRACTA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIRACTA THERAPEUTICS INC worth?
VIRACTA THERAPEUTICS INC (VIRX) has a market capitalization of 3.09M USD. This makes VIRX a Nano Cap stock.
How many employees does VIRACTA THERAPEUTICS INC have?
VIRACTA THERAPEUTICS INC (VIRX) currently has 40 employees.
What are the support and resistance levels for VIRACTA THERAPEUTICS INC (VIRX) stock?
VIRACTA THERAPEUTICS INC (VIRX) has a resistance level at 0.15. Check the full technical report for a detailed analysis of VIRX support and resistance levels.
Should I buy VIRACTA THERAPEUTICS INC (VIRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VIRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VIRX, evaluating the profitability, health, valuation and growth aspects
- VIRACTA THERAPEUTICS INC (VIRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIRACTA THERAPEUTICS INC (VIRX) Sales and EPS estimates to see what analysts future expectations are.
- VIRACTA THERAPEUTICS INC (VIRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIRACTA THERAPEUTICS INC (VIRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIRACTA THERAPEUTICS INC (VIRX) Stock Chart to make your own analysis
- VIRACTA THERAPEUTICS INC (VIRX) Latest news and press-releases to stay up to date.
Does VIRACTA THERAPEUTICS INC (VIRX) stock pay dividends?
VIRX does not pay a dividend.
When does VIRACTA THERAPEUTICS INC (VIRX) report earnings?
VIRACTA THERAPEUTICS INC (VIRX) will report earnings on 2025-03-05, after the market close.
What is the Price/Earnings (PE) ratio of VIRACTA THERAPEUTICS INC (VIRX)?
VIRACTA THERAPEUTICS INC (VIRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.1).
What is the Short Interest ratio of VIRACTA THERAPEUTICS INC (VIRX) stock?
The outstanding short interest for VIRACTA THERAPEUTICS INC (VIRX) is 0.06% of its float. Check the ownership tab for more information on the VIRX short interest.
VIRX Technical Analysis
VIRX Financial Highlights
Over the last trailing twelve months VIRX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 11.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VIRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to VIRX. The Buy consensus is the average rating of analysts ratings from 6 analysts.